Results from a study evaluating the efficacy of (100) nivolumab alone or in combination with ipilimumab in RCC patients (154) showed that patients with lower levels of FH and complement factor D (FD) had a less favorable response to ICIs, whereas patients with reduced levels of complement factor I (FI) and TCC were associated with better responses and prolonged periods without tumor progression. This evidence concerns the gene FH and renal cell carcinoma.